Saudi Pharmaceutical Industries and Medical Appliances Corp
Last Updated:
- 32.35 SAR
- -0.35
- -1.07%
الشركة السعودية للصناعات الدوائية والمستلزمات الطبية
الدوائية
Symbol :
2070
ISIN :
SA0007879188
52-Week Range :
24.92
-
42.85
Turnover Ratio :
1.97
Market :
Saudi Exchange
Sector :
Pharma, Biotech & Life Science
Industry :
Pharmaceuticals and Biotechnology Research & Development
Sub-Industry :
Basic Information
-
Activity :Saudi Pharmaceutical Industries and Medical Appliances Corp (known as: SPIMACO) is a public company, listed on Saudi Stock Exchange “Tadawul” (TDWL) since October 1993. SPIMACO operates within the Pharmaceuticals,...
-
Industry Group :pharmaceuticals Research and Biotechnology
-
Sub-Industry :
-
ISIN :SA0007879188
-
Contact Person :
-
Established On:20-Jan-1986
-
Stock Listing On :31-Oct-1993
-
No of Employees :1,200 Employees as of 2018
-
Outstanding Shares :120,000,000
-
Free Float Shares :
-
Par Value :
-
Paid Capital :
-
Market Cap :
-
Authorized Capital :
Indices Membership
| Action | Date | Index | Provider |
|---|---|---|---|
| Join | 2017 | Pharma, Biotech & Life Science | Saudi Exchange Co |
| Leave | 2017 | Industrial Investment | Saudi Exchange Co |
| Join | 1993 | Industrial Investment | Saudi Exchange Co |
| Join | 1993 | Tadawul All Share Index (TASI) | Saudi Exchange Co |
| Saudi Pharmaceutical Industries and Medical Appliances Corp |
| Prince Salman Bin Muhammed Bin Saud street - AS SAHAFAH P.O.Box 20001 Riyadh 11455, Kingdom of Saudi Arabia |
| T : +966 11 2523320 |
| F : +966 11 2523300 |
| www.spimaco.com.sa |
| investor.relations@spimaco.sa |
Management
| Title | Name | As Of |
|---|---|---|
| Chairman: | Ahmed Aljedai | 2023 |
| CEO: | Jerome Cabannes | 2023 |
| Deputy Chairman: | Ammar Al Khudairy | 2019 |
| Board Member: | Khalid Al Gwaiz | 2019 |
| Abdulrahman Al Thinyan | 2022 | |
| Faisal Shaker | 2019 | |
| Fahad Al Rabiah | 2022 | |
| Mai AlAjaji | 2022 | |
| Mohammad Mohammad | ||
| Adill Ahmed |
Reports
| Date | Title | File |
|---|---|---|
| 2024 | SPIMACO Quarterly Financials Report Q2 2024 | |
| 2024 | SPIMACO reports SAR 134 million EBITDA with a 15.8% EBITDA margin in 1H 2024 | |
| 2024 | SPIMACO Announces Partnership with Altos Biologics for Production and Commercialisation of ALT-L9, Biosimilar to Aflibercept, across MENA | |
| 2024 | SPIMACO Quarterly Financials Report Q1 2024 | |
| 2024 | SPIMACO Announces SAR 40 million net income in 1Q 2024 | |
| 2024 | SPIMACO Annual Financials Report 2023 | |
| 2024 | SPIMACO Maintains Top Position in Private Sector with Consistent Revenue Growth in FY 2023 | |
| 2024 | SPIMACO Confirms Jerome Cabannes as CEO | |
| 2024 | SPIMACO Forges Strategic Alliance with Recbio for Recombinant HPV-9 Vaccine | |
| 2023 | SPIMACO to Acquire Osmopharm, a Swiss Pharmaceutical Drug Delivery Innovator | |
| 2023 | SPIMACO Quarterly Financials Report Q3 2023 |
